Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FLUCON study of continuous flucloxacillin dosing
NL-OMON43049Recruiting
- Sponsor
- Deventer Ziekenhuis
- Start
- Jan 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label trial of flucloxacillin in bacterial disease (2 arms), sponsored by Deventer Ziekenhuis. Primary endpoints: Population pharmacokinetics of flucloxacillin, Derived continuous dosing regimen and 1 more. Started Jan 2017; status: recruiting.
02
Drugs
flucloxacillin
03
Conditions
bacterial disease
Beyond the preview
Go deeper on NL-OMON43049.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON43049.